Cost effectiveness of heart drugs varies widely, study showsBMJ 2007; 334 doi: http://dx.doi.org/10.1136/bmj.39199.472361.DB (Published 03 May 2007) Cite this as: BMJ 2007;334:922
- Roger Dobson
The cost effectiveness of treatments for coronary heart disease varies more than 100-fold, a new study shows.
It found that the cost for each life year gained of aspirin and ß blockers for secondary prevention after a heart attack worked out at less than £1000 (€1500; $2000), whereas the cost of statins used for primary prevention in men aged 35–44 was around £70 000 (Quarterly Journal of Medicine 2007;100:277-89).
“Large amounts of NHS funding are being spent on relatively less cost effective interventions, such as statins for primary prevention, angioplasty, and coronary artery bypass graft surgery. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial